Nanoparticles as Novel Solutions to Microbial Resistance in Hospital Care

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antimicrobial Materials and Surfaces".

Deadline for manuscript submissions: closed (31 January 2026) | Viewed by 1063

Special Issue Editor


E-Mail Website
Guest Editor
Department of Chemistry, Biochemistry and Biophysics, University of Veterinary Medicine and Pharmacy, Komenského 73, 041 81 Košice, Slovakia
Interests: organic synthesis; phytochemistry; antioxidant activity; green synthesis; nanoparticles; antimicrobial activity
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nosocomial infections, also referred to as healthcare-associated infections, are infections acquired during the process of healthcare. Various pathogenic microorganisms, including bacteria, viruses, and fungi, are responsible for these infections, and also for increasing the mortality of patients due to multidrug resistant species, such as methicillin-resistant, and vancomycin-resistant Staphylococcusaureus, vancomycin-resistant Enteroccocus, carbapenem-resistant species of Enterobacteriaceae and Actinobacter, or multi-drug-resistant Pseudomonas aeruginosa, and many others.

Metal nanoparticles represent a promising way to prevent these infections. Mainly silver nanoparticles have been established as an alternative to fight against multi-drug-resistant microorganisms. In addition to their ability to inhibit the growth of microorganisms, silver nanoparticles exhibit unique properties that make them a suitable choice against these bacteria, as silver nanoparticles are highly biocompatible and easy to use in medical applications.

For this Special Issue, we are looking for manuscripts that deal with the use of metallic nanoparticles to prevent/avoid nosocomial infections, and contribute to our understanding of multi-drug-resistant microorganisms inhibition mechanisms.

Dr. Zdenka Bedlovičová
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanoparticles
  • antibiotic resistance
  • nosocomial infections
  • MRSA
  • VRSA
  • antimicrobial properties
  • multi-drug resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

24 pages, 5539 KB  
Article
Effect of Biosynthesized Gold and Silver Nanoparticles Using Alchemilla vulgaris Extract and Their Synergistic Action with Subinhibitory Concentrations of Ampicillin Against Staphylococci
by Ján Király, Gabriela Gregová, Patrícia Hudecová, Vanda Hajdučková, Simona Hisirová, Nikola Dančová, Peter Takáč, Valéria Verebová and Zdenka Bedlovičová
Antibiotics 2026, 15(3), 250; https://doi.org/10.3390/antibiotics15030250 - 27 Feb 2026
Viewed by 477
Abstract
Background: Staphylococci, recognized for their virulence and antibiotic resistance, are important in both human and veterinary medicine. Loss of sensitivity to beta-lactam antibiotics, such as ampicillin, complicates therapy, prompting the search for alternative antibacterials or ways to increase drug efficacy. Silver and gold [...] Read more.
Background: Staphylococci, recognized for their virulence and antibiotic resistance, are important in both human and veterinary medicine. Loss of sensitivity to beta-lactam antibiotics, such as ampicillin, complicates therapy, prompting the search for alternative antibacterials or ways to increase drug efficacy. Silver and gold nanoparticles (AgNPs, AuNPs) are promising on their own or in combination with antibiotics. Methods: The aim of this study is to compare the biological activity of pure, washed AgNPs and AuNPs with biosynthesized nanoparticles from Alchemilla vulgaris (AgNPs-Av and AuNPs-Av). Their antibacterial, antibiofilm, and biofilm-eradication effects on the tested antibiotic-resistant, biofilm-forming staphylococci (Methicillin-resistant Staphylococcus aureus (MRSA) and multiresistant Non-aureus staphylococci and mammaliicocci (NASM)) were evaluated using in vitro microdilution methods. Results: AgNPs-Av and AuNPs-Av inhibited bacterial growth at 50 μg/mL, while a significant suppression of biofilm formation was observed at just 25 μg/mL. Our research showed that neither AuNPs-Av nor AuNPs disrupts bacterial biofilm. AgNPs-Av effectively eradicated the biofilm at 50 μg/mL. NPs and ampicillin at subinhibitory antibiotic concentrations against the tested staphylococci. The results showed significant antibacterial and antibiofilm effects (p = 0.001). Partially, biofilm-eradication activity and strong antibiotic potentiation were also detected. Conclusions: These findings highlight the importance of rational combination therapy to improve antibiotic effectiveness and reduce bacterial resistance. Full article
Show Figures

Figure 1

Back to TopTop